# Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma

> **NCT00131937** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Peripheral T-cell Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00131937
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-09
- **Final completion:** 2012-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2015-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131937, "Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00131937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*